Results from the phase 2 trial of ridaforolimus, dalotuzumab, and exemestane compared to ridaforolimus and exemestane in advanced breast cancer. San Antonio Breast Cancer Symposium 2014; PD5-1 - Rugo, H S; Tredan, O; Ro, J
et al.